Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations. Today, we announce the launch of two new products: GSD NovaPrime® Plus SARS-CoV-2, a PCR test which can detect, in one reaction, key mutations of variants of concern, present for example in the UK variant; and GSD NovaType Select L452R SARS-CoV-2 (RUO) the first test of its type able to detect critical variants such as the Indian, USA and Californian variants. Eurofins Technologies will continue to invest in R&D to develop further reliable, high-quality testing solutions for the SARS-CoV-2 virus and its variants.
GSD NovaPrime® Plus SARS-CoV-2 kit is a multiplex RT-PCR that can detect a SARS-CoV-2 infection and identify mutations of concern in one reaction. The assay detects mutations N501Y and/or E484K in the spike protein which have demonstrated clinical and epidemiological impact and are carried by virus variants of concern such as B.1.1.7 (UK), B.1.351 (South Africa), and B.1.1.248 (P.1) (Brazil) / B.1.525 (Nigeria) / V2 (UK) / B.1.1.28 (Brazil) / B.1.526 (New York) / B.1.1.318 (Nigeria).
GSD NovaType Select L452R SARS-CoV-2 (RUO) is the latest launch from Eurofins Technologies, a singleplex assay for the detection of the mutation L452R occurring with SARS-CoV-2 variants of concern or variants of interest B.1.427 / B.1.429 (USA California; 20C/S452R), B.1.526.1 (USA), and B.1.617 (India). It is of relevance to the global pandemic situation as this mutation is related to both an increase in infectivity and reduction of immune response in vaccinated subjects. This singleplex assay can be also used in tandem with the recently CE marked test GSD NovaType II SARS-CoV-2 which facilitates the discrimination of variants of interest and concern N501Y, E484K as well as the detection of the mutation K417N (specific to B.1.351 South Africa) on selected positive samples.